Publication
Urothelial carcinoma with an NRF1-BRAF rearrangement and response to targeted therapy.
Authors not recorded
Cold Spring Harb Mol Case Stud2019PMID 31010895PMC6549557stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerTransitional Cell Carcinomacivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31010895
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF Fusion1 | ||||||||
| Trametinib | Transitional Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7763In a case report, a patient with metastatic urothelial carcinoma harboring an NRF1-BRAF fusion was treated with trametinib. After two and a half months of treatment, MRI revealed 48.4% decrease in siz… (full text at CIViC) PMID 31010895 · Isaacson et al., 2019 · Open in CIViC | civic |